retatrutide parkinson clinical trial Lilly Prepares for FDA Filing Following Additional Phase 3 Data in Diabetes, CVD retatrutide clinical trial parkinson Triple

Big changes

This trial highlights the groundbreaking role of GLP-1 receptor agonists, traditionally used for managing diabetes, in reducing cardiovascular risk among individuals with overweight and obesity, even in the absence of diabetes

However, cortical bone thickness was decreased in the semaglutide group ( P = 0.032), while no significant changes in bone microarchitecture or biomechanical strength were noted

& Moenter, S

This substantial weight loss not only improves overall health and quality of life but also contributes to better management of type 2 diabetes

Candidate panels include MRI-PDFF, ELF, PRO-C3, and emerging transcriptomic signatures